- Home
- HHH vs KNSA Comparison
HHH vs KNSA Comparison
Compare HHH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHH | KNSA |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United Kingdom |
| Employees | 500 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HHH | KNSA |
|---|---|---|
| Price | $61.38 | $46.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $90.00 | $55.29 |
| AVG Volume (30 Days) | 543.2K | ★ 653.7K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 2.21 | 0.75 |
| Revenue | ★ $1,474,892,000.00 | $677,564,000.00 |
| Revenue This Year | $14.04 | $38.01 |
| Revenue Next Year | N/A | $17.42 |
| P/E Ratio | ★ $28.05 | $60.87 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $61.41 | $18.26 |
| 52 Week High | $91.07 | $49.12 |
Technical Indicators
Market Signals| Indicator | HHH | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 52.36 |
| Support Level | N/A | $39.96 |
| Resistance Level | $71.26 | $48.29 |
| Average True Range (ATR) | 1.68 | 1.78 |
| MACD | -0.31 | -0.15 |
| Stochastic Oscillator | 0.11 | 58.41 |
Price Performance
Historical ComparisonAbout HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.